FASN inhibitor G28UCM inhibited the growth of HER2+ BC and even in patients with acquired resistance to anti-HER2 drugs, which may provide a new way to treat trastuzumab-resistant BC [125]. This evidence concerns the gene ERBB2 and breast cancer.